Click here to search courses using NAPNAP's previous Course Catalog layout.

Event date
  • Primary Care
  • FREE for Members
  • Pharmacology CE
  • 1.00 Contact hours
1.0 NAPNAP contact hour, 1.0 pharmacology contact hour. This continuing education activity is offered free to NAPNAP Members. For non-members, this continuing education activity rate is $10. Before 2018, there were no U.S. Food and Drug Administration approved medications for managing seizures in Dravet syndrome (DS). Common agents used in the antiepileptic drug regimens of patients with DS included clobazam, valproic acid, topiramate, and levetiracetam, among others; however, these agents alone rarely provide adequate seizure control. Management of seizures in DS changed in recent years with the approval of cannabidiol and stiripentol in 2018 and fenfluramine in 2020. This continuing education article summarizes available efficacy and safety data involving cannabidiol, stiripentol, and fenfluramine and provides a practical review of dosing strategies, pharmacokinetics, and monitoring interventions relevant to their use. J Pediatr Health Care. (2022) 36, 479−488